[A21-57] Nivolumab (NSCLC) - Addendum to Commission A20-118
Last updated 04.06.2021
Commission awarded on 29.04.2021 by the Federal Joint Committee (G-BA).
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation
Patients with PD-L1 expression (TPS) ≥ 50%: added benefit not proven.
Patients with PD-L1 expression (TPS) < 50% and brain metastases: indication of an added benefit; extent “considerable”.
Patients with PD-L1 expression (TPS) < 50% without brain metastases: indication of an added benefit; extent “minor”.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A20-118||Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.